Day: April 27, 2021

DUBLIN, IRELAND, April 27, 2021 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 fourth quarter and full year financial results at 11:00 a.m. ET on Wednesday, May 19, 2021. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing fourth quarter and full year financial results will be issued after the U.S. market closes on Tuesday, May 18, 2021. For those unable to listen to the conference call live, a replay will be available beginning at 1:00 p.m. ET on May 19, 2021, either at www.steris-ir.com or via phone. To access the replay of the call, please use the...

BRAINTREE, Mass., April 27, 2021 (GLOBE NEWSWIRE) — Altra Industrial Motion Corp. (Nasdaq: AIMC), a leading global manufacturer and supplier of motion control, power transmission and automation products, today announced that its Board of Directors has approved the payment of a quarterly cash dividend of $0.08 per share for the second quarter of 2021. The second quarter 2021 dividend is the thirty-seventh consecutive dividend in the Company’s history. The dividend will be paid on July 2, 2021 to shareholders of record as of the close of business on June 18, 2021. Future declarations of quarterly cash dividends are subject to approval by the Board of Directors and to the Board’s continuing determination that the declaration of dividends is in the best interests of Altra’s shareholders and is in compliance with all laws...

VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) — Uniserve Communications Corporation (“Uniserve”) (TSX.V: USS) a provider of IT solutions and services to business and residential customers in Canada wishes to announce third quarter fiscal 2021 financial results. Q3 and Q3 year to date fiscal 2021 revenues decreased by 36% and 33% respectively as compared to the same periods in the prior fiscal year. Q3 fiscal 2021 Net Profit was $24K and Q3 year to date fiscal 2021 Net loss was $294K, as compared to Net loss of $1,002K and Net loss of $2,385K respectively for the prior year fiscal periods. In upcoming quarters the Company will continue focusing on generating recurring revenue through new higher profit margin product offerings while continuing to focus on cost savings.Uniserve Communications Corporation    Condensed...

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) — New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) announced today that it completed a private placement to eligible purchasers of $100 million in aggregate principal amount of the Company’s 5.75% senior unsecured notes due April 2026 at 100% of par. The Company intends to use the net proceeds from the offering to originate new investments, repay outstanding indebtedness and for general corporate purposes. Piper Sandler & Co. served as placement agent for the offering. The notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and, unless so registered, the securities may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to,...

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present data highlighting its proprietary base editing approach in several presentations during the 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021. In addition, Beam has been selected as a workshop presenter in the pre-meeting program taking place on May 10, 2021. “Since our founding in 2017, we have been diligently focused on advancing our proprietary base editing technology to develop treatments for patients suffering from severe diseases, and we are pleased to present updates showcasing the potential of our technology during ASGCT,” said Giuseppe...

ATLANTA, April 27, 2021 (GLOBE NEWSWIRE) — HAVERTYS (NYSE: HVT and HVT.A), today reported strong operating results for the first quarter ended March 31, 2021. First quarter 2021 versus first quarter 2020:Diluted earnings per common share (“EPS”) of $1.04 versus $0.09. Stores closed March 19, 2020 and deliveries halted March 21, 2020 in response to the COVID-19 pandemic. Consolidated sales increased 31.8% to $236.5 million. Comparable store sales increased 11.5%.Clarence H. Smith, chairman and CEO, said, “We are pleased to see our teams’ hard work translate to continued sales and earnings growth. The high pace of demand for home furnishings, which started during the second quarter of 2020, has not slowed. Our first quarter written business this year was up 10.8% over the fourth quarter of 2020. We are addressing our staffing...

— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes — SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced data from its fusogen technology platform, which are being presented at the virtual American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2021. The data to be presented demonstrate in vivo gene delivery to T cells and hepatocytes using a re-targetable fusogen delivery method. Sana is developing fusogens as a platform technology to enable the delivery of genetic payloads to specific cell types. Fusogens can bind to cell-surface proteins on the target cell type and then deliver the genetic payload...

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced three digital presentations at the American Society of Gene & Cell Therapy (ASGCT) 2021 Virtual Annual Meeting taking place May 11-14. The presentations will cover data supporting use of the company’s platform for antibody gene therapy, a summary of previously released preclinical data from the hemophilia A program and insight into ceDNA construct engineering for factor VIII. “We look forward to sharing preclinical data supporting the broad potential of our platform in antibody gene therapy and to providing an overview of our lead hemophilia A program,” said Matthew Stanton, Ph.D., chief scientific officer of Generation Bio. “The hemophilia...

PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) — Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentation at the upcoming American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting held virtually May 11-14, 2021. Data to be presented includes evidence of in vitro molecular efficacy with KB501 (expressing a TNF-α targeting antibody), and in vivo proof-of-concept in two models of atopic dermatitis with KB501 and KB502 (expressing an IL-4Rα targeting antibody). “The ability to deliver sustained antibody expression locally in the target tissue of interest opens up exciting new strategic optionality for our platform,” said Suma Krishnan, founder and...